Company news

Acrux Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Acrux receives $1.73m advance on FY25 R&D Tax Incentive

April 2, 2025

Investor Presentation February 2025

February 25, 2025

Appendix 4D and December 2024 Half Year Accounts

February 25, 2025

Acrux CEO announces plan to retire

February 6, 2025

Monthly Activities/Appendix 4C Cash Flow Report

January 29, 2025

Launch of 90 gram pack size of Dapsone 5%, Gel in US

January 15, 2025

Acrux raises $1.34 million from SPP

December 22, 2024

Investor Deck update, SPP Closes 18 December 2024, 5pm

December 17, 2024

Commercialisation of Nitroglycerin Ointment

December 12, 2024

Share Purchase Plan Offer Booklet

December 5, 2024

Investor Presentation

December 5, 2024

Share Placement successfully concluded and SPP launched

December 4, 2024

FDA Approval - Nitroglycerin Ointment

December 3, 2024

Trading Halt

December 2, 2024

AGM Presentation

November 20, 2024

FY24 R&D Tax Incentive rebate received

October 1, 2024

ASX Small and Mid Cap Conference presentation

September 23, 2024

FY24 Full Year Results - Investor Presentation

August 29, 2024

Appendix 4E and FY24 Full Year Statutory Accounts

August 29, 2024

FDA Approval received for Dapsone Gel, 7.5%

August 26, 2024

Quarterly Activities Report and Appendix 4C - June 2024

July 25, 2024

Acrux presentation to Bioshares, 18th Biotech Summit

July 14, 2024

RDTI funding facility secured

June 27, 2024

Acrux presentation at Hidden Gems in Lifesciences Forum

June 12, 2024

Launch of Dapsone 5%, Gel in the United States

April 2, 2024

Investor Presentation Half Year Accounts

February 27, 2024

Appendix 4D and Half Year Accounts

February 27, 2024

Appendix 4C and Activities Statement

January 30, 2024

Address of Chair and CEO to AGM

November 28, 2023

Acrux receives $2.88m R&D Tax Incentive Rebate for FY23

November 7, 2023

Investor Presentation - Acrux FY23 Results

August 24, 2023

Appendix 4E and FY23 Annual Report

August 24, 2023

Activities Statement and Appendix 4C

July 26, 2023

Acruxs seventh generic dossier accepted by FDA for review

July 3, 2023

4th FDA ANDA approval received - Dapsone Gel, 5%

June 7, 2023

Appendix 4D and Half Year Report

February 23, 2023

Quarterly Activities / Appendix 4C Cashflow Report

January 29, 2023

Gedeon Richter buyout Lenzetto Royalties for EUR4.1million

January 22, 2023

Launch of prilocaine and lidocaine cream in United States

December 20, 2022

Mutual Termination of Co-Development Agreement

December 15, 2022

Chairman and CEO address to AGM

November 22, 2022

Remaining balance of R&D Tax Incentive Rebate received

October 2, 2022

Appendix 4E and FY22 Annual Report

August 25, 2022

Acruxs sixth generic dossier accepted by FDA for review

August 7, 2022

Acrux announces commercial agreement with Padagis

June 20, 2022

Successful patent litigation outcome

May 29, 2022

Appendix 4D, Half Year Accounts as at 31 December 2021

February 24, 2022

Acrux and Harris terminate license agreement

October 10, 2021

Acruxs fifth generic dossier accepted by FDA for review

September 12, 2021

Acrux Investor Presentation - September 2021

September 1, 2021

← Newer news releases · Older news releases →

Decks

The 5 newest of 62 decks. Every deck is listed under its year.